JPWO2022178244A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022178244A5 JPWO2022178244A5 JP2023550043A JP2023550043A JPWO2022178244A5 JP WO2022178244 A5 JPWO2022178244 A5 JP WO2022178244A5 JP 2023550043 A JP2023550043 A JP 2023550043A JP 2023550043 A JP2023550043 A JP 2023550043A JP WO2022178244 A5 JPWO2022178244 A5 JP WO2022178244A5
- Authority
- JP
- Japan
- Prior art keywords
- braf
- cancer
- pharma
- acceptable salt
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 93
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 93
- 150000003839 salts Chemical class 0.000 claims description 43
- 206010028980 Neoplasm Diseases 0.000 claims description 42
- 201000011510 cancer Diseases 0.000 claims description 37
- 230000035772 mutation Effects 0.000 claims description 31
- 229940124647 MEK inhibitor Drugs 0.000 claims description 28
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 28
- 229940126062 Compound A Drugs 0.000 claims description 27
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 27
- 230000004927 fusion Effects 0.000 claims description 21
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 claims description 16
- 102000043136 MAP kinase family Human genes 0.000 claims description 12
- 108091054455 MAP kinase family Proteins 0.000 claims description 12
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical group OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 claims description 11
- 229950002592 pimasertib Drugs 0.000 claims description 11
- 102200055517 rs121913348 Human genes 0.000 claims description 11
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 claims description 10
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 claims description 10
- 102200055466 rs121913364 Human genes 0.000 claims description 10
- 102200055529 rs121913351 Human genes 0.000 claims description 9
- 101000626153 Homo sapiens Tensin-3 Proteins 0.000 claims description 8
- 206010069755 K-ras gene mutation Diseases 0.000 claims description 8
- 101710029140 KIAA1549 Proteins 0.000 claims description 8
- 102100024548 Tensin-3 Human genes 0.000 claims description 8
- 102100022865 UPF0606 protein KIAA1549 Human genes 0.000 claims description 8
- 230000037361 pathway Effects 0.000 claims description 8
- 102200055537 rs121913355 Human genes 0.000 claims description 8
- 102200055534 rs121913357 Human genes 0.000 claims description 8
- 102200006541 rs121913530 Human genes 0.000 claims description 8
- 102100036779 Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 3 Human genes 0.000 claims description 7
- 101000928222 Homo sapiens Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 3 Proteins 0.000 claims description 7
- 102200055461 rs121913366 Human genes 0.000 claims description 7
- 102200006539 rs121913529 Human genes 0.000 claims description 7
- 102200006538 rs121913530 Human genes 0.000 claims description 7
- 230000005856 abnormality Effects 0.000 claims description 6
- VWMJHAFYPMOMGF-ZCFIWIBFSA-N TAK-580 Chemical compound N([C@H](C)C=1SC(=CN=1)C(=O)NC=1N=CC(Cl)=C(C=1)C(F)(F)F)C(=O)C1=NC=NC(N)=C1Cl VWMJHAFYPMOMGF-ZCFIWIBFSA-N 0.000 claims description 5
- 229950010746 selumetinib Drugs 0.000 claims description 5
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims description 5
- -1 BRAF-AGAP3 Proteins 0.000 claims description 4
- 102100030708 GTPase KRas Human genes 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 102200055464 rs113488022 Human genes 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000007667 Cytochrome P-450 CYP2C19 Inhibitors Diseases 0.000 claims description 3
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 claims description 3
- 208000000130 Cytochrome P-450 CYP3A Inducers Diseases 0.000 claims description 3
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 claims description 3
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 claims description 3
- 101100523539 Mus musculus Raf1 gene Proteins 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 230000000306 recurrent effect Effects 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 102100040084 A-kinase anchor protein 9 Human genes 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 102100022388 Acylglycerol kinase, mitochondrial Human genes 0.000 claims description 2
- 102100028493 Armadillo repeat-containing protein 10 Human genes 0.000 claims description 2
- 108010092778 Autophagy-Related Protein 7 Proteins 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 102100039195 Cullin-1 Human genes 0.000 claims description 2
- 102100040351 FK506-binding protein 15 Human genes 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 206010064571 Gene mutation Diseases 0.000 claims description 2
- 101000890598 Homo sapiens A-kinase anchor protein 9 Proteins 0.000 claims description 2
- 101000769233 Homo sapiens Armadillo repeat-containing protein 10 Proteins 0.000 claims description 2
- 101000746063 Homo sapiens Cullin-1 Proteins 0.000 claims description 2
- 101000891018 Homo sapiens FK506-binding protein 15 Proteins 0.000 claims description 2
- 101001008857 Homo sapiens Kelch-like protein 7 Proteins 0.000 claims description 2
- 101000654664 Homo sapiens Neuronal-specific septin-3 Proteins 0.000 claims description 2
- 101001111328 Homo sapiens Nuclear factor 1 A-type Proteins 0.000 claims description 2
- 101000633708 Homo sapiens Src kinase-associated phosphoprotein 2 Proteins 0.000 claims description 2
- 101000891092 Homo sapiens TAR DNA-binding protein 43 Proteins 0.000 claims description 2
- 101000785641 Homo sapiens Zinc finger protein with KRAB and SCAN domains 1 Proteins 0.000 claims description 2
- 102100027789 Kelch-like protein 7 Human genes 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 102100032769 Neuronal-specific septin-3 Human genes 0.000 claims description 2
- 102100024006 Nuclear factor 1 A-type Human genes 0.000 claims description 2
- 102100037375 SLIT-ROBO Rho GTPase-activating protein 3 Human genes 0.000 claims description 2
- 101150083405 SRGAP3 gene Proteins 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 102100029213 Src kinase-associated phosphoprotein 2 Human genes 0.000 claims description 2
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 claims description 2
- 108091007283 TRIM24 Proteins 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 102100022011 Transcription intermediary factor 1-alpha Human genes 0.000 claims description 2
- 102100026463 Zinc finger protein with KRAB and SCAN domains 1 Human genes 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 102000016613 Autophagy-Related Protein 7 Human genes 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 69
- 102000007530 Neurofibromin 1 Human genes 0.000 description 4
- 108010085793 Neurofibromin 1 Proteins 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 230000037442 genomic alteration Effects 0.000 description 3
- 102000016914 ras Proteins Human genes 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 102100029974 GTPase HRas Human genes 0.000 description 2
- 102100039788 GTPase NRas Human genes 0.000 description 2
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229950003054 binimetinib Drugs 0.000 description 2
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 102200006532 rs112445441 Human genes 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- OCUQMWSIGPQEMX-UHFFFAOYSA-N 3-[3-[N-[4-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-1H-indol-6-yl]-N-ethylprop-2-ynamide Chemical compound CCNC(=O)C#CC1=CC2=C(C=C1)C(=C(N2)O)C(=NC3=CC=C(C=C3)CN(C)C)C4=CC=CC=C4 OCUQMWSIGPQEMX-UHFFFAOYSA-N 0.000 description 1
- 102100039602 ARF GTPase-activating protein GIT2 Human genes 0.000 description 1
- 102100028243 Breast carcinoma-amplified sequence 1 Human genes 0.000 description 1
- LMMJFBMMJUMSJS-UHFFFAOYSA-N CH5126766 Chemical compound CNS(=O)(=O)NC1=NC=CC(CC=2C(OC3=CC(OC=4N=CC=CN=4)=CC=C3C=2C)=O)=C1F LMMJFBMMJUMSJS-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102100031048 Coiled-coil domain-containing protein 6 Human genes 0.000 description 1
- 102100021183 E3 ubiquitin-protein ligase RNF130 Human genes 0.000 description 1
- 102100036334 Fragile X mental retardation syndrome-related protein 1 Human genes 0.000 description 1
- ZEZHPEIEEFTILY-QMMMGPOBSA-N G-573 Chemical compound C[C@H](O)CONC(=O)C=1OC2=C(F)C=NC=C2C=1NC1=CC=C(I)C=C1F ZEZHPEIEEFTILY-QMMMGPOBSA-N 0.000 description 1
- RFWVETIZUQEJEF-UHFFFAOYSA-N GDC-0623 Chemical compound OCCONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F RFWVETIZUQEJEF-UHFFFAOYSA-N 0.000 description 1
- 102100034155 Guanine nucleotide-binding protein G(i) subunit alpha-1 Human genes 0.000 description 1
- 102100034473 H(+)/Cl(-) exchange transporter 6 Human genes 0.000 description 1
- 101000888642 Homo sapiens ARF GTPase-activating protein GIT2 Proteins 0.000 description 1
- 101000935635 Homo sapiens Breast carcinoma-amplified sequence 1 Proteins 0.000 description 1
- 101000777370 Homo sapiens Coiled-coil domain-containing protein 6 Proteins 0.000 description 1
- 101000930945 Homo sapiens Fragile X mental retardation syndrome-related protein 1 Proteins 0.000 description 1
- 101001070526 Homo sapiens Guanine nucleotide-binding protein G(i) subunit alpha-1 Proteins 0.000 description 1
- 101000710240 Homo sapiens H(+)/Cl(-) exchange transporter 6 Proteins 0.000 description 1
- 101000726740 Homo sapiens Homeobox protein cut-like 1 Proteins 0.000 description 1
- 101001050622 Homo sapiens KH domain-containing, RNA-binding, signal transduction-associated protein 2 Proteins 0.000 description 1
- 101000578920 Homo sapiens Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 Proteins 0.000 description 1
- 101000761460 Homo sapiens Protein CASP Proteins 0.000 description 1
- 101000882133 Homo sapiens Protein FAM131B Proteins 0.000 description 1
- 101000628676 Homo sapiens STARD3 N-terminal-like protein Proteins 0.000 description 1
- 101000834926 Homo sapiens Transmembrane protein 106B Proteins 0.000 description 1
- 102100023411 KH domain-containing, RNA-binding, signal transduction-associated protein 2 Human genes 0.000 description 1
- 102100028322 Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 Human genes 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 102100024933 Protein CASP Human genes 0.000 description 1
- 102100038972 Protein FAM131B Human genes 0.000 description 1
- 108091007333 RNF130 Proteins 0.000 description 1
- 102100026752 STARD3 N-terminal-like protein Human genes 0.000 description 1
- 102100026232 Transmembrane protein 106B Human genes 0.000 description 1
- 102100022979 Ubiquitin-like modifier-activating enzyme ATG7 Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 101150048834 braF gene Proteins 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960002271 cobimetinib Drugs 0.000 description 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical group OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229950008933 refametinib Drugs 0.000 description 1
- 102200024198 rs121909329 Human genes 0.000 description 1
- 102220053950 rs121913238 Human genes 0.000 description 1
- 102200085789 rs121913279 Human genes 0.000 description 1
- 102200006531 rs121913529 Human genes 0.000 description 1
- 102200007373 rs17851045 Human genes 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163151425P | 2021-02-19 | 2021-02-19 | |
| US63/151,425 | 2021-02-19 | ||
| US202163173158P | 2021-04-09 | 2021-04-09 | |
| US63/173,158 | 2021-04-09 | ||
| PCT/US2022/016962 WO2022178244A1 (en) | 2021-02-19 | 2022-02-18 | Combination of raf inhibitor and mek inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024507221A JP2024507221A (ja) | 2024-02-16 |
| JP2024507221A5 JP2024507221A5 (https=) | 2025-02-27 |
| JPWO2022178244A5 true JPWO2022178244A5 (https=) | 2025-02-27 |
Family
ID=82931723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023550043A Pending JP2024507221A (ja) | 2021-02-19 | 2022-02-18 | Ｒａｆ阻害剤とｍｅｋ阻害剤の組合せ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240058338A1 (https=) |
| EP (1) | EP4294400A4 (https=) |
| JP (1) | JP2024507221A (https=) |
| KR (1) | KR20230147136A (https=) |
| AU (1) | AU2022223437A1 (https=) |
| CA (1) | CA3211167A1 (https=) |
| IL (1) | IL305250A (https=) |
| MX (1) | MX2023009642A (https=) |
| WO (1) | WO2022178244A1 (https=) |
| ZA (1) | ZA202307921B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4408430A4 (en) * | 2021-10-01 | 2025-07-30 | Day One Biopharmaceuticals Inc | RAF KINASE INHIBITORS FOR THE TREATMENT OF TUMORS WITH GENE FUSIONS |
| WO2025106686A1 (en) * | 2023-11-15 | 2025-05-22 | Day One Biopharmaceuticals, Inc. | Methods of treating pediatric low-grade glioma |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104428001A (zh) * | 2012-03-30 | 2015-03-18 | 武田药品工业有限公司 | Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与 |
| CA3240745A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatment using combinations of erk and raf inhibitors |
| UY36046A (es) * | 2014-03-26 | 2015-10-30 | Millennium Pharm Inc | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso |
| WO2016025648A1 (en) * | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a raf inhibitor and related methods |
| AU2018329925B2 (en) * | 2017-09-08 | 2025-05-29 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for cancer |
-
2022
- 2022-02-18 MX MX2023009642A patent/MX2023009642A/es unknown
- 2022-02-18 KR KR1020237031421A patent/KR20230147136A/ko active Pending
- 2022-02-18 JP JP2023550043A patent/JP2024507221A/ja active Pending
- 2022-02-18 WO PCT/US2022/016962 patent/WO2022178244A1/en not_active Ceased
- 2022-02-18 CA CA3211167A patent/CA3211167A1/en active Pending
- 2022-02-18 AU AU2022223437A patent/AU2022223437A1/en not_active Abandoned
- 2022-02-18 EP EP22756995.1A patent/EP4294400A4/en active Pending
- 2022-02-18 IL IL305250A patent/IL305250A/en unknown
-
2023
- 2023-08-15 ZA ZA2023/07921A patent/ZA202307921B/en unknown
- 2023-08-16 US US18/450,638 patent/US20240058338A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7114575B2 (ja) | Ｒａｆ阻害剤及びｅｒｋ阻害剤を含む治療用組合せ | |
| Drilon et al. | A phase I/Ib trial of the VEGFR-sparing multikinase RET inhibitor RXDX-105 | |
| JP2024019720A (ja) | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ | |
| JP2019532051A5 (https=) | ||
| JP2014505658A5 (https=) | ||
| KR20230157379A (ko) | 소토라십 투약 요법 | |
| CN117355306A (zh) | 索托拉西布给药方案 | |
| JP2026053570A (ja) | Ｋｒａｓ ｇ１２ｃ変異を含む癌を治療するためのソトラシブ及びｅｇｆｒ抗体 | |
| Janku et al. | Dose‐escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF‐mutated advanced cancers | |
| JPWO2022178244A5 (https=) | ||
| WO2023049363A1 (en) | Sotorasib and afatinib for treating cancer comprising a kras g12c mutation | |
| Yudong et al. | EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: R esponse to apatinib and clinical outcomes | |
| Yasuoka et al. | Efficacy and safety of axitinib therapy after nivolumab for patients with metastatic renal cell cancer | |
| TW202304438A (zh) | 使用貝伐拉非尼及考比替尼或使用貝伐拉非尼、考比替尼及阿替利珠單抗的組合療法 | |
| Kwon et al. | Predictive factors for switched EGFR-TKI retreatment in patients with EGFR-mutant non-small cell lung cancer | |
| KR20230031839A (ko) | 암 치료에 사용하기 위한 벨바라페닙 | |
| JP5881671B2 (ja) | チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法 | |
| JPWO2020219668A5 (https=) | ||
| RU2774612C2 (ru) | Терапевтические комбинации, содержащие ингибитор raf и ингибитор erk | |
| CN116981462A (zh) | 索托拉西布给药方案 | |
| Agarwala | Evolving Considerations in the Treatment and Management of Metastatic Melanoma: Expert Strategies on Immune Checkpoint Inhibitors | |
| Gumma et al. | Breaking resistance barriers: ensartinib as a milestone in anaplastic lymphoma kinase–driven non-small cell lung cancer therapy | |
| Rose | New Data on HER2-Targeted Drugs for NSCLC Deemed “Impressive” | |
| Farag-Kal | Improving diagnosis and treatment of gastrointestinal stromal tumor (GIST) patients: Results from the Dutch GIST Registry | |
| Omar et al. | Real-World Pharmacovigilance Analysis of Lenvatinib Use in Qatar |